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1. Introduction  38 
 39 
Multiple sclerosis (MS) is a chronic inflammatory neurological disease of the central nervous system. 40 
It is one of the most common causes of neurological disability in adults as its peak onset is in people 41 
aged between 20 and 40 years, with an increased prevalence in women [1]. Diagnosis is based on the 42 
clinical and neuroradiological (i.e., magnetic resonance imaging – MRI) evidence of disease 43 
dissemination in space and time, and on the exclusion of alternative diagnoses [2]. The diagnostic 44 
criteria have changed over time to improve specificity and sensitivity and to allow an earlier diagnosis 45 
[3]. People presenting with a first neurological event highly suggestive of MS, but who do not meet the 46 
full criteria for a diagnosis of MS, are classified as having a clinically isolated syndrome (CIS) [4]. CIS 47 
is defined as a monophasic neurologic event (usually an optic neuritis or a focal myelitis) lasting for at 48 
least 24 hours caused by inflammation and demyelination within the central nervous system [5]. The 49 
symptoms usually develop within hours or days and they must be associated to objective neurological 50 
signs found in MRI or spinal fluid examination [5]. 51 
 52 
Previous systematic reviews have recognized depressive and anxiety symptoms in MS without the 53 
distinction of the disease duration [6,7], but similar systematic reviews on emotional outcomes have 54 
not yet been performed in CIS. The prevalence of depressive symptoms in MS is extremely variable, 55 
ranging from 5 to 60% [8] with four times higher risk of depression compared to the general population 56 
[9]. Despite this, emotional outcomes are often underestimated in clinical practice, as formal 57 
psychological evaluations are infrequent and symptoms undertreated [8,10–12]. Physical symptoms and 58 
non-specific symptoms such as fatigue and cognitive problems, which are common both to MS and 59 
affective disorders, also hinder the identification of depression and anxiety [6]. Also, symptomatic 60 
treatments in MS tend to focus more often on the physical rather than emotional outcomes [6].  61 
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 62 
Previous studies have reported that the prevalence of depressive symptoms may be lower in the 63 
relapsing remitting course of MS than in the progressive course, and in the secondary course more than 64 
in the primary progressive courses [13]. However, some evidence suggests otherwise as depression was 65 
found to relate only partially to higher disability [14], and some studies observed an inverse correlation 66 
between depressive symptoms and disease duration [15,16]. Therefore, the direction of causation is not 67 
yet clear. A higher prevalence of anxiety has been reported in the initial phases of the disease, which is 68 
explained by the need to adapt to a chronic and unpredictable disease [17]. Recent systematic reviews 69 
have highlighted the prevalence of depression (31%) and anxiety (22%) [7] and the relationship between 70 
anxiety symptoms and increased disability and low quality of life in people with MS [18]. However, 71 
both reviews focused on MS without the distinction of the disease duration. Early phase MS represents 72 
a critical period during which the person assigns meaning to the disease, with consequences on 73 
treatment decisions and symptom adaptations [19]. The first years after the MS diagnosis may represent 74 
an important time-frame, in which helping people to build an active disease adjustment could improve 75 
disease and treatment decision-making, adherence to treatments, and could prevent development of 76 
psychiatric disorders [20].  77 
 78 
Depression in MS is not only a strong predictor for reduced health-related quality of life (HRQoL) 79 
independent of disability [21], but is also highly correlated with suicidality symptoms [22]. People with 80 
MS are 1.8–7.5 times more likely to die by suicide compared to the general population, and the risk is 81 
particularly high in the first year after the diagnosis, stressing the importance of identifying depressive 82 
symptoms in the early years of MS [23]. For HRQoL in MS, quality of life is reduced mainly due to the 83 
impact of physical disability on daily life functioning [24]. People with MS have reported a greater 84 
decline in perceived physical health than in mental health functioning in 10-year general-population 85 
studies [25,26]. Perceived emotional outcomes of HRQoL instruments, such as emotional well-being, 86 
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have shown improvement in 10-year follow-up studies although no change has been found in overall 87 
mental health [26,27]. However, there is not yet been extensive review evaluation of emotional HRQoL 88 
in CIS and in early phase MS. 89 
 90 
To our knowledge, no systematic review has been conducted on the prevalence and relationships of 91 
depressive and anxiety symptoms and disorders in CIS and in early phase MS. Based on clinical 92 
evidence, we conducted a systematic review in CIS and early phase MS with the following aims:  93 
1) To quantify the prevalence of depression and anxiety, 94 
2) To estimate the pooled mean symptoms scores of depression and anxiety, 95 
3) To estimate the associations between pooled mean symptoms scores of depression and 96 
anxiety and study characteristics, 97 
4) To determine the strength of any association of emotional HRQoL with depressive and 98 
anxiety symptoms, 99 
5) To determine the prevalence of suicide risk and suicidality symptoms and their relation 100 
with depressive and anxiety symptoms. 101 
 102 
2. Method 103 
 104 
2.1. Search strategy 105 
 106 
A systematic literature search was conducted using four databases: Cumulative Index to Nursing and 107 
Allied Health Literature (CINAHL), Comprehensive Biomedical Literature Database (EMBASE), 108 
Archive of Biomedical and Life Sciences Journal Literature (PubMed), and the Behavioral and Social 109 
Science Research (PsycInfo). The first search was performed for studies published until 3rd April 2017. 110 
An updated search was conducted using the same databases for studies between 1st April 2017 until 1st 111 
October 2018. A combined flow chart of study selection is presented in Figure 1. The protocol for this 112 
systematic review has been registered on the Prospective Register of Systematic Reviews (PROSPERO) 113 
and can be accessed at  114 
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https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=68909. 115 
 116 
Inclusion criteria were designed by members of the research team and were checked with the patient 117 
advisory board in the European research consortium: Remote Assessment of Disease and Relapse – 118 
Central Nervous System (RADAR-CNS) which included people with direct experience of MS. 119 
Inclusion criteria were adults (18 years of age or older) with CIS and adults with a maximum of 5 years 120 
since the diagnosis of MS (hereafter, early phase MS). As there is no clear international consensus for 121 
the classification of “early phase MS”, we decided to include patients with MS who received a diagnosis 122 
within five years before the study assessment. This choice was based on a comprehensive search of the 123 
definition of the early phase of MS from previous studies which resulted in a heterogeneous range from 124 
zero [28] to six [29] years since diagnosis. Depending on the year of the study, diagnosis of MS was 125 
defined either by McDonald or Poser criteria [2,30–32]. 126 
 127 
Studies were also required to report outcomes of depression, anxiety, life satisfaction, suicide 128 
risk/suicidality symptoms, or HRQoL in CIS or in early phase MS. Only studies published in English 129 
were included in the review. Study samples consisting of only adolescents (under 18 years) and studies 130 
including other or similar diagnoses without a separate analysis of people with MS or CIS were 131 
excluded. The corresponding authors of the studies were contacted for further information if these 132 
criteria were inadequately reported. Previous systematic reviews, interventional and qualitative studies, 133 
and study protocols were also excluded.  134 
 135 
Two researchers (A.R. and S.S.) performed the searches in the selected databases in collaboration with 136 
the research team. In addition to this, a patient advisory board of people with experience of living with 137 
MS were consulted about the most important questions to ask and outcomes of interest (see 138 
supplementary file). The final search terms included various medical subject headings (MeSH) or 139 
keyword headings describing emotional effects (e.g., depression, anxiety, stress, distress, mood, 140 
stressor) and terms related to MS and CIS. Additionally, to capture the terminology related to the 141 
diagnosis time of MS, we used time-related terms such as “first stage”, “onset”, “early phase”, and 142 
“recently diagnosed”. The original search strategy is available in Appendix 1. 143 
 144 
2.2. Data extraction 145 
 146 
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Three reviewers (A.R. and M.R./G.L.) independently screened the studies in line with the Preferred 147 
Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines [33,34]. An updated 148 
search was conducted also by three reviewers (A.R. and F.M./S.S.). After the screening of the studies 149 
based on their title and abstract, relevant studies were independently evaluated for full-text assessment. 150 
In case of a disagreement, a fourth assessor evaluated the studies. If needed, the corresponding authors 151 
of the included studies were contacted for further information. 152 
 153 
2.3. Methodological quality of the studies 154 
 155 
Methodological quality of the included observational studies was assessed independently by two pairs 156 
of reviewers (M.R./G.L. and V.B./C.B.) using the 14-item Quality Assessment Tool for Observational 157 
Cohort and Cross-Sectional Studies [35–37]. An item was scored positive (Yes) if the criterion was 158 
fulfilled, negative (No), or other (Other) if inadequately reported or not applicable. The total score of a 159 
study reflected the total sum of positive scores. The maximum score was 14 points. Overall quality 160 
rating per study was assessed either good, fair, or poor where good indicates the least risk of bias (≥ 10 161 
points), a “fair” study indicates some bias not sufficient to have a major impact to its results (6–9 points), 162 
and “poor” indicates a significant risk of bias (≤ 5 points) [35].  163 
 164 
2.4. Statistical synthesis 165 
 166 
Study and participant characteristics were extracted and a descriptive analysis was performed on all 167 
outcomes. Agreement level between the reviewers was assessed using Cohen’s Kappa [38]. Pooled 168 
prevalence estimates and mean values for depression and anxiety were calculated via pairwise meta-169 
analysis for CIS and MS groups separately. For both prevalence and pooled mean meta-analyses, 170 
heterogeneity was assessed using I2, with values of 25%, 50% and 75% representing low, moderate and 171 
high heterogeneity respectively [39], and meta-analyses were only conducted if a minimum of 2 papers 172 
could contribute to the analysis. 173 
 174 
Depression and anxiety prevalence data were collected into categories of “mild”, “moderate” and 175 
“severe” symptoms, combining different questionnaires with thresholds relating to these definitions. To 176 
incorporate as much data as possible, additional categories of “any depression” and “any anxiety” were 177 
created, to reflect all the studies, which reported cases of depression according to one threshold as 178 
opposed to levels of severity. Due to anticipated high levels of heterogeneity, random-effects meta-179 
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analyses with 95% confidence intervals (CIs) were conducted with each screening tool at each 180 
threshold, using the “metaprop” command for Stata (version 14.0), with ftt subcommand [40]. Missing 181 
prevalence data were requested from the authors of the primary research, and not included if data were 182 
unavailable. 183 
 184 
Pooled mean and standard error (SE) scores for depression, anxiety and HRQoL were meta-analysed 185 
taking into account the random-effects for anticipated heterogeneity using the “metan” package for 186 
Stata (version 14.0) [41]. This process was conducted for depression and anxiety separately. Missing 187 
SE data were imputed from all other available information, including SD data. If no SD data were 188 
available, missing data were imputed by calculating the mean SD from data available in other studies 189 
reporting outcomes from the same questionnaires. Studies with missing mean data were excluded from 190 
the meta-analyses. 191 
 192 
Meta-regression was used to investigate the relationship between study-level characteristics and pooled 193 
mean depression, anxiety, and to explain the possible heterogeneity. A priori decisions were made to 194 
investigate the study-level characteristics: sample mean age; the proportion of female gender; sample 195 
size; time since experiencing symptoms; time since diagnosis; disease severity; publication year; 196 
proportion of the sample still in employment; and overall study quality. All characteristics were treated 197 
as continuous variables and analysed individually as univariate meta-regression models. The results of 198 
the meta-regression show the relationship between these study characteristics and variability in meta-199 
analysis outcomes, with the beta indicating the increase or decrease in pooled mean score associated 200 
with a 1-unit change in these study-level characteristics. Results are also reported with SE, 95% CI, and 201 
adjusted-R2. 202 
 203 
3. Results 204 
 205 
The literature search identified 1841 studies after removing duplicate studies. Screening of 374 full-text 206 
studies retrieved 51 studies that fulfilled the inclusion criteria. Within those 51 studies, 39 studies 207 
focused on early phase MS, 10 studies on CIS, and two studies on both disease conditions. A flow chart 208 
of the screening process is presented in Figure 1, and individual study information is reported in 209 
Appendixes 2 to 4. Agreement level between the reviewers yielded a value of 0.71 indicating substantial 210 
agreement (0.61–0.80) in the title screening, a value of 0.50 indicating a moderate agreement (0.41–211 
0.60) in the abstract screening, and 0.84 indicating excellent agreement (0.81–0.99) in the full-text 212 
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screening. The update search yielded 0.88 in the title screening, 0.81 in the abstract screening, and 0.83 213 
in the full-text screening. 214 
 215 
3.1. Description of the participants 216 
 217 
The selected studies included a total of 3,498 participants, of which 2,896 were people with early phase 218 
MS and 602 with CIS. 219 
 220 
Early phase MS. Participants with early phase MS had the mean (SD) age of 36.3 (4.2, range 29.9–221 
52.0) years and sixty-seven percent of them were female. Mean (SD) disease duration was 16.8 (10.5, 222 
range 2.0–49.5) months from the onset of diagnosis, and 95% had relapsing-remitting MS. Disease 223 
severity were reported in 21 (51%) studies with a median (interquartile range) of 1.8 (1.6–2.4) in the 224 
Expanded Disability Status Scale (EDSS) and one study reporting the median (range) of 2.0 (0–6) in 225 
the Patient Determined Disease Steps (PDDS). Only 19 (46%) studies reported any medication related 226 
to MS, and of those studies, 83% (N = 1162) of participants with early phase MS used a disease-227 
modifying treatment (DMT) or other symptomatic treatments related to MS. Only four studies reported 228 
antidepressant (N = 26), anxiety (N = 6), or combination of different psychiatric medication (N = 79) 229 
[17,42–44].   230 
  231 
CIS. The mean (SD) age was 34.9 (2.9) years and average (SD) disease duration was 12.3 (8.6) months. 232 
Fifty percent of CIS diagnosed participants were female. Disease severity was assessed by EDSS in 233 
eight (67%) studies with median (interquartile range) disease severity of 1.1 (1.0–1.7), respectively. 234 
Five studies reported medication, and of those studies, fifteen percent of people with CIS used DMT. 235 
Only one study reported the use of antidepressant (N = 16) [44]. 236 
 237 
3.2. Methodological quality and the risk of bias  238 
 239 
The overall methodological quality of the studies was fair (Table 4). Most of the studies were 240 
characterized by good data presentation and validated measures for the assessment of emotional 241 
outcomes. The major issue in the quality of studies was the small sample sizes, which limited the 242 
precision of the findings. Other common limitations included failure to report the timing of study period 243 
and clear description of eligible population, which increased the risk of possible selection bias. In 244 
addition, the majority of the studies did not report the blindness status of the assessors. 245 
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 246 
3.3. The prevalence of depression and anxiety 247 
 248 
Early phase MS. Prevalence of depression in MS was reported in 18 out of 34 studies (53%) that 249 
investigated depression (Appendix 2). Prevalence estimates varied from 0% to 82% [17,28,51–250 
58,42,44–50]. Table 1 shows the results of the prevalence meta-analyses, with the most robust analyses 251 
(with four or more studies) also shown as a forest plot in Figure 2. Pooled prevalence estimates for 252 
depression ranged between 0% and 37%, with severe depression (representing the BDI with a threshold 253 
of > 29 and the Montgomery-Åsberg Depression Rating Scale (MADRS) with a threshold of > 34) and 254 
the Diagnostic and Statistical Manual (DSM) diagnostic criteria for MDD yielding the lowest and 255 
highest point prevalence estimates, respectively. 256 
 257 
Prevalence of anxiety was reported in 9 out of 16 studies (Appendix 2) [17,44,46,47,49,55,57–59]. Cut-258 
off points of anxiety prevalence estimates varied across studies and the prevalence estimates ranged 259 
from 8% to 64%. The most commonly used tool to identify possible anxiety symptoms was the HADS-260 
A (Table 1); this was used in five included studies (N = 589) using a threshold of > 7 and 1 study with 261 
a threshold of > 8. Results of this meta-analysis indicate a prevalence of 49%. No other anxiety 262 
measures were used often enough to provide meta-analysed prevalence estimates. 263 
 264 
CIS. Only four out of 10 CIS studies reported prevalence estimates of depressive symptoms that ranged 265 
from 22% to 30% (Appendix 3) [44,60–62]. Only two studies reported the prevalence estimates of 266 
anxiety symptoms with HADS-A values of 36% (N = 124) and 100% (N = 56) [44,62]. Both prevalence 267 
estimates indicated that mild depressive and anxiety symptoms are present among people with CIS. 268 
 269 
3.4. Depressive and anxiety symptom burden 270 
 271 
Early phase MS. Data were available from four measures assessing depressive symptoms – the Beck 272 
Depression Inventory (BDI), the depression scale of Hospital Anxiety Depression Scale (HADS-D), 273 
Hamilton Depression Scale (HAM-D), and the Symptom Checklist-90 item (SCL-90). Depressive 274 
symptoms varied from a normal state to moderate (Table 2). Meta-regression results of 12 studies with 275 
530 participants showed no association between study-level characteristics for BDI outcomes (Table 276 
3). However, meta-regression of seven studies with 696 participants observed a significant relationship 277 
between sample size (β = 0.01; 95% CI: 0.00 to 0.02; p = 0.03) and study quality (β = 0.38; 95% CI: 278 
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0.05 to 0.71; p = 0.03) and overall pooled mean HADS-D outcome (4.55; 95% CI: 3.41 to 5.69; p < 279 
.0001; I2 = 93.2). This indicates that a one-unit increase in sample size and study quality is associated 280 
with a 0.01 and 0.38 increase in mean depression scores, respectively. 281 
 282 
Mean anxiety data were available for four different anxiety measures - the Beck Anxiety Inventory 283 
(BAI), State Trait Anxiety Inventory (STAI), the anxiety symptom scale of HADS (HADS-A), and 284 
SCL-90. Anxiety symptoms varied from a normal state to mild (Table 2). HADS-A data of seven studies 285 
with 696 participants were sufficient for meta-regression (Table 3). Results of this analysis showed a 286 
significant relationship between sample size (β = 0.04; 95% CI: 0.02 to 0.06; p < .01) and pooled mean 287 
HADS-A outcomes (6.31; 95% CI: 5.79 to 6.83; p < .0001; I2 = 61.2). This indicates that a one-unit 288 
increase in sample size is associated with a 0.04 increase in mean HADS-A score. 289 
 290 
CIS. Eleven CIS studies used five different instruments to assess depressive symptoms (Appendix 3) 291 
[44,60,69,61–68]. The most frequently used questionnaire was BDI, which allowed for a meta-analysis 292 
of four studies (Table 2). Overall pooled mean depression was 7.1 (95% CI: 5.55 to 8.65; p < .001), 293 
which indicated that the mean score for BDI was below recognized thresholds for depression. 294 
 295 
Anxiety in CIS was investigated in three prospective cohort [60,62,67] and three cross-sectional 296 
[44,63,64] studies (Appendix 3). Not enough data were reported in these studies to combine them 297 
meaningfully in meta-analysis. The most commonly used measurement was the HADS-A questionnaire 298 
in three studies [44,62,64], but only one of these studies reported the anxiety data that indicated a normal 299 
state in anxiety symptoms among 38 participants with CIS [64]. Mild anxiety symptoms were reported 300 
in two studies using the STAI instrument [60,67] and in one study using the BAI instrument [63]. 301 
 302 
3.5. Emotional HRQoL and its association with emotional outcomes 303 
 304 
Early phase MS. Thirteen studies used an outcome of HRQoL (Appendix 4) [43,44,75,76,46,54,67,70–305 
74]. Five different HRQoL instruments were identified, with most studies using the 54-item Multiple 306 
Sclerosis Quality of Life (MSQOL-54) questionnaire [43,54,67,70,74]. Total mental health summary 307 
scores of MSQOL-54 ranged from 53.4 to 69.6 points out of 100 [43,54,67,70]. Second most used 308 
HRQoL questionnaire was the 36-Item Short Form Survey (SF-36) [46,71,75,76], but only one reported 309 
mean mental health composite score of 56.8 out of 100 [76]. Four studies reported that emotional 310 
HRQoL emotional were correlated or associated with depression outcomes regardless of the HRQoL 311 
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measurement (Appendix 4) [46,73,74,77]. Only one study reported a difference between early phase 312 
MS and healthy participants, and indicated that the SF-36 mental health composite score and domain 313 
of mental health were reduced in people with early phase MS compared with healthy participants [75]. 314 
Follow-up studies did not find a change in emotional HRQoL in early phase MS, when MSQOL-54 315 
was observed after 30 months [67] and SF-36 after 12 months [46]. 316 
 317 
CIS. Four studies investigated HRQoL with three different measurements – the Functional Assessment 318 
of Multiple Sclerosis (FAMS), MSQOL-54, and the French version of MSQOL-54 (SEP-54) (Appendix 319 
4) [44,66,67,78]. One study found a correlation between the FAMS total score and the Multiple 320 
Sclerosis Neuropsychological Questionnaire, and one study with a 30-month follow-up revealed no 321 
change in total mental health composite score in MSQOL-54 [67].  322 
 323 
3.6. Suicide risk and/or suicidality symptoms 324 
 325 
Three studies reported a subgroup analysis of suicide risks within five years from the MS diagnosis 326 
[23,79,80]. Comparing to later phases of MS, Brønnum-Hansen et al. [2005] observed an increased risk 327 
of 3.2 (standard mortality ratio) for suicide within the first year after diagnosis [23]. Fredrikson et al., 328 
[2003] and Stenager et al. [1992] found suicide was the most common cause of death, comprising 58% 329 
of all mortality in 5 years following diagnosis [79]. Our search results did not find CIS studies 330 
investigating suicide or suicidality symptoms. 331 
 332 
4. Discussion  333 
 334 
The purpose of this systematic review and meta-analysis was to investigate emotional outcomes in 335 
people with CIS and early phase MS. The two main findings are that mild-to-moderate depressive and 336 
anxiety symptoms are common in CIS and early phase MS, and that low emotional health-related 337 
quality of life linked to depression and an increased suicide risk were observed in early phase MS. 338 
Meta-regression analyses revealed an increase in mean HADS-D and HADS-A associated with larger 339 
sample size, and higher HADS-D mean with increased study quality. Our findings are comparable with 340 
previous studies that focused on later phases of MS [7–9,18,81], which also confirmed a higher 341 
prevalence of emotional distress in MS compared to the general population [8,9,81].  342 
 343 
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Early phase MS. Our meta-analysis of three studies with 114 participants indicated a prevalence of 344 
37% for major depressive disorder according to DSM criteria and we identified a decrease in prevalence 345 
according to depression severity, identified through combining cases identified with different 346 
questionnaire thresholds representing “mild”, “moderate” and “severe” depression. Given that the 347 
criteria for a diagnosis of DSM major depressive disorder are more strict, it is surprising that we found 348 
a higher prevalence of major depressive disorder than of a broader array of depressive symptoms as 349 
measured with a questionnaire. However, the small number of included studies in the meta-analysis 350 
indicates that these results should be interpreted with caution and more research is required to provide 351 
more robust data for meta-analysis. Although the number of studies in these meta-analyses were low, 352 
these findings indicate that depressive symptoms are common in the early years of MS. Our results for 353 
depressive symptoms are in line with the previous studies that investigated longer disease duration of 354 
MS. A systematic review of 58 studies estimated the prevalence of depression to be 31%, but with high 355 
level of heterogeneity [7].  356 
 357 
Similar findings were also observed on anxiety symptoms in early phase MS. Anxiety prevalence 358 
estimates were observed with a range of 8% to 64% and our meta-analysis indicated that 35% of 589 359 
participants experienced anxiety symptoms (HADS-A). These findings support previous studies that 360 
reported anxiety in 19% to 36% of the patients with a longer disease duration of MS (i.e., 14–19 years), 361 
suggesting that anxiety is present and common in MS [21,82,83]. Compared to previous studies, our 362 
findings might indicate that anxiety symptoms are similar or even slightly higher in early phase MS 363 
compared to later phase of MS. The high prevalence of anxiety may reflect the population under 364 
investigation. There is some evidence to suggest that shorter disease duration is associated with 365 
increased anxiety, with the recency of diagnosis and adjustments to illness potentially having immediate 366 
implications for anxiety symptoms [18,84]. Future research could test this hypothesis more robustly to 367 
examine longitudinal change in anxiety symptoms as disease duration increases. This is particularly 368 
important as a previous study has found that anxiety disorders are overlooked and under-treated in MS 369 
[21]. Adequate treatment of anxiety symptoms may help the patients in the process of disease 370 
acceptance and diminish the risk of developing a depression. 371 
 372 
To investigate heterogeneity in our findings, our meta-regression from seven studies with 696 373 
participants revealed that an increase in mean HADS-D and HADS-A was associated with larger sample 374 
size, and higher HADS-D mean was associated with increased study quality. These findings indicate 375 
that studies with higher sample sizes might capture depression and anxiety symptoms more accurately, 376 
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and findings captured with HADS-D might be influenced by the study quality. However, our results did 377 
not indicate associations with disease duration or EDSS, which supports previous findings [83]. This 378 
might indicate that depressive and anxiety symptoms might be persisting, or persons with MS are 379 
experiencing these symptoms at different times. The lack of studies prevented us from investigating the 380 
influence of disease-modified treatments, which might have an effect on emotional outcomes in early 381 
phase MS. 382 
 383 
Emotional health-related quality of life was mainly investigated as a predictor in the early phases of 384 
MS rather than as an outcome of observational studies. We observed several limitations such as the low 385 
number of studies, lack of reporting values on quality of life, and wide variety of measurements used. 386 
The individual quality of life varied across included studies. In sum, quality of life measurements did 387 
not indicate emotional burden, and follow-up studies did not find a change in mental health, when 388 
MSQOL-54 was observed after 30 months [67] and SF-36 after 12 months [46]. However, four studies 389 
reported that the emotional quality of life was correlated or associated with either depression, disease 390 
severity, or other emotional-related outcomes regardless of the quality of life measurement 391 
[46,73,74,77]. This might indicate that people with early phase MS experiencing depression or other 392 
emotional challenges also reported decline in emotional quality of life. This also supports the evidence 393 
from previous MS reviews, who focused on longer disease duration [24,85]. Only three studies 394 
investigated suicide risk within five years of the MS diagnosis, indicating an increased risk of suicide 395 
in the early years of MS when it was compared to the later phases of MS [23,79,80]. Previous studies 396 
have reported a higher suicide risk within MS population comparing to healthy population [86,87]. Our 397 
conclusion on health-related quality of life and suicide risk/suicidality symptoms indicates that these 398 
phenomena have been investigated quite poorly in the first five years of MS onset. 399 
 400 
CIS. In our descriptive analysis findings, the prevalence of depressive symptoms ranged from 22% to 401 
30% [44,60–62] and in anxiety from 36% to even 100% [44,62]. Our meta-analysis included four 402 
studies using BDI indicated minimal depressive symptoms in persons with CIS (N=92). Although the 403 
number of included studies and study samples were low, these findings suggest that both depression 404 
and anxiety are similarly present both in CIS. Previous individual studies have found conflicting 405 
evidence, either indicating that emotional disturbances such as depressive symptoms are present among 406 
people with CIS [60], or that there is no indication of differences on depression and anxiety between 407 
CIS and healthy controls [63].  408 
 409 
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Emotional health-related quality of life in CIS were in the same direction as in early phase MS, but the 410 
lack of included studies and variety of used measurements prohibited firm conclusions on the possible 411 
impact of emotional quality of life in CIS. Only one 30-month follow-up study revealed no change in 412 
total mental health composite score in MSQOL-54 over time [67]. One aim of this review was to 413 
evaluate the suicide risk and suicidality symptoms in CIS, but our search did not identify any studies 414 
investigating outcomes of these in CIS. Because of the lack of evidence, there is no clear understanding 415 
of the emotion-related quality of life or suicide risk and suicidality symptoms in people with CIS, how 416 
it might change over time, or influence other physical and psychological outcomes.  417 
 418 
Study strengths and limitations 419 
 420 
The major strength of this review is the focus on emotional outcomes in CIS and early phase MS. To 421 
our knowledge, this is the first systematic review to investigate these outcomes in both conditions. One 422 
strength of this study is also to involve people with a direct experience of MS in the research process to 423 
share their view of the findings. Comments of the patient advisory board was asked in every stages of 424 
the review study. Our results offers important insight into emotional burden in both conditions, and will 425 
hopefully guide future studies to focus on psychological aspects of CIS and early phase MS, in order to 426 
understand the emotional impact of these conditions on daily life functioning. We need more 427 
observational studies to gather evidence-based knowledge on emotional effects for both conditions, 428 
which might guide clinicians to take into account the emotional burden in their clinical decision-making 429 
process. 430 
 431 
This review also has some limitations. The major issue in the quality of studies was the small sample 432 
sizes, which limited the precision of the findings. Other common limitations included a failure to report 433 
the timing of study and a clear description of the eligible population, both of which will increase the 434 
risk of selection bias. Another key limitation, which has been reported in other depression prevalence 435 
meta-analyses in physical disease [88], is the wide range of questionnaires and thresholds used to 436 
identify the presence of depression and anxiety. A total of 12 depression questionnaires and 7 anxiety 437 
questionnaires were used with a range of different, often seemingly arbitrary thresholds, were used to 438 
identify cases. This makes pooling data into meaningful categories for comparison with the general 439 
population or other disease groups challenging, and one clear direction for future research would be to 440 
attempt to standardise how mental disorders are reported to allow cross-study comparisons. Clinical 441 
and statistical findings were heterogeneous with more studies sensitivity and subgroup analyses might 442 
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identify factors to explain this heterogeneity. One additional limitation as a study selection bias may 443 
also be that our search strategy was not extended to grey-literature sources. Despite these limitations, 444 
we believe that our review gives important insight in the emotional effects of CIS and early phase MS, 445 
which hopefully will raise the awareness to investigate these effects more in the future. 446 
 447 
Recommendations for future research 448 
 449 
Depression in MS might be caused by a reaction to the presence of the disease and the consequent 450 
implications on daily life or a biological damage of the central nervous system that impact on the normal 451 
functioning of affectivity and emotion regulation. Our findings support the need of an appropriate 452 
psychological evaluation after the diagnosis, as depression may develop already in the early phases, 453 
confirming that mood disorders are partially related to disability. The major challenge to understand the 454 
prevalence estimates of depression is the variability in the instruments used to measure depression, and 455 
the wide range of thresholds used to define cases. This is one of the major limitations highlighted also 456 
by the recent American Academy of Neurology (AAN) guidelines [6]. Only 52% of included studies 457 
reported cut-off threshold points of depression, which demonstrates a lack of reporting depression in 458 
early phase MS. We recommend for the future studies to report depression prevalence estimates using 459 
measures with validated thresholds.  460 
 461 
To confirm our findings in our review, we recommend more longitudinal observational studies to 462 
monitor depressive and anxiety symptoms, health-related quality of life, and suicidal ideas and 463 
behaviours in both conditions, especially to the time point once the diagnosis of MS is defined. Insight 464 
into the emotional disturbances in the transition phase of CIS and MS may be informative to help people 465 
with their possible emotional burden in an uncertain time after diagnosis. Finally, we recommend future 466 
studies to involve people with a direct experience of MS in the research process. 467 
 468 
5. Conclusion 469 
 470 
This systematic review suggests that mild-to-moderate depressive and anxiety symptoms might be 471 
present in CIS and in early phase MS. Future research on both clinical populations are needed, 472 
especially longitudinal monitoring of emotional outcomes. 473 
 474 
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Table 1. Prevalence meta-analysis in early phase multiple sclerosis. 764 
Questionnaire Measures (thresholds; N of papers) Total N papers  Total Sample Prevalence (%) 95% CI p 
% I2 (Tau 
2) 
DEPRESSION        
Mild depression1 BDI (10-18; 2) MADRS (7-19; 2) 4 127 24 15.0, 34.0 <0.001 30.3 (0.0) 
Moderate depression2 BDI (19-29; 2) MADRS (20-34; 2) 4 127 5 1.0, 12.0 <0.001 35.6 (0.0) 
Severe depression3 BDI (>29; 2) MADRS (>34; 1) 3 89 0 0.0, 2.0  1.00 0.0 (0.0) 
Any depression4 
BDI (>8; 1) BDI (>9; 1) HADS (>7; 4) HADS (>8; 1) HAMD (>13; 
1) CESD (>10; 1) 9 752 25 17.0, 35.0 <0.001 86.7 (0.1) 
DSM MDD 3 114 37 28.0, 46.0 <0.001 0.0 (0.0) 
ANXIETY        
Any anxiety5 HADS (>7; 5) HADS (>8; 1) 6 645 49 27.0, 72.0 <0.001 97.1 (0.3) 
N Number. CI Confidence Interval. I2 I-Squared Heterogeneity. 1Mild depression categorised by combing "mild" thresholds on BDI (Beck Depression Inventory - 10-18) and MADRS 
(Montgomery-Asberg Depression Rating Scale - 7-19). 2Moderate depression categorised by combing "moderate" thresholds on BDI (19-29) and MADRS (20-34). 3Severe depression 
categorised by combing "moderate" thresholds on BDI (>29) and MADRS (>34).HADS-D Hospital Anxiety & Depression Scale - Depression. 4Any depression categorised through 
participants scoring above the lowest reported threshold on any scale: BDI (>8); BDI (>9); HADS (>7); HADS (>8); Hamilton Depression Scale (HAMD, >13); Centre for Epidemiological 
Studies Depression scale (CESD, >10). DSM Diagnostic and Statistics Manual. MDD Major Depressive Disorder. AD Adjustment Disorder. 5Any anxiety categorised through participants 
scoring above the lowest reported threshold on any scale: HADS (>7); HADS (>8).  
 765 
 766 
 767 
 768 
 769 
 770 
 771 
 772 
Table 2. Mean scores of depressive and anxiety symptoms in early phase multiple sclerosis and clinically isolated syndrome. 773 
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Questionnaire Pooled Mean (95% CI) N studies 
N 
participants p-value I2 (Tau2) 
Interpretation 
Depression       
BDI, 0–63 (MS) 7.32 (5.63 to 9.02) 12 530 < .0001 93.9 (7.0) Minimal depressive symptoms (0 – 9) 
BDI, 0–63 (CIS) 7.10 (5.55 to 8.65) 4 92 < .001 0.0 (0.0) Minimal depressive symptoms (0 – 9) 
HADS-D, 0–21(MS) 4.55 (3.41 to 5.69) 7 696 < .0001 93.2 (2.1) Normal state (0 – 7) 
HAM-D, 0–54 (MS) 12.65 (8.05 to 17.25) 2 75 < .0001 86.6 (9.6) Moderate depressive symptoms (11 – 14) 
CES-D (MS) 11.20 (9.90 to 14.50) 2 123 < .0001 77.0 (4.5) No clinical significance ( < 16) 
SCL-90*, 0–5 (MS) 1.31 (-0.23 to 2.85) 2 67 .09 98.9 (1.2) Minimal depressive symptoms 
Anxiety       
BAI, 0–63 (MS) 11.38 (8.78 to 13.98) 2 47 < .0001 0.0 (0.0) Mild anxiety symptoms (10 – 18) 
STAI, 20–80 (MS) 42.59 (40.03 to 45.16) 3 354 < .0001 76.3 (3.9) Mild anxiety symptoms 
HADS-A, 0–21 (MS) 6.31 (5.79 to 6.83) 7 696 < .0001 61.2 (0.3)  Normal state (0 – 7) 
SCL-90*, 0–5 (MS) 1.16 (-0.36 to 2.68) 2 67 .13 99.2 (1.2) Minimal anxiety symptoms 
N = number; 95% CI = 95% Confidence Interval; I2 = I-Squared Heterogeneity; BDI = Beck Depression Inventory;  HADS-D = Hospital Anxiety & 774 
Depression Scale – Depression; HAM-D = Hamilton Depression Scale; CES-D = The Center for Epidemiologic Studies Depression Scale; SCL-90 = 775 
Symptom Checklist - 90 item; STAI = State Trait Anxiety Inventory; HADS-A = Hospital Anxiety & Depression Scale – Anxiety; MS early phase 776 
multiple sclerosis; CIS = Clinically isolated syndrome. 777 
* Included studies calculated SCL-90 scores by using a general severity index (GSI) from mean of 9 subscales (0–5). 778 
 779 
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Table 3. Univariate meta-regression analysis of covariates and pooled mean depressive and anxiety 
symptoms in early phase MS. 
Depression 
Pooled Mean (95% 
CI) N studies N sample p-value I2 (%) 
BDI, 0–63 7.32 (5.63 to 9.02) 12 530 < .0001* 93.9 
Covariates Beta (SE) Lower CI Upper CI p-value R-squared (%) 
Age -0.05 (0.10) -0.27 0.17 .65 0 
Percentage female gender -0.02 (0.04) -0.10 0.06 .61 0 
Sample size 0.00 (0.00) -0.01 0.01 .62 0 
Disease duration -0.05 (0.06) -0.18 0.08 .44 0 
EDSS -1.21 (1.21) -4.00 1.59 .65 100 
Study Quality 0.02 (0.17) -0.35 0.39 .93 . 
Publication Year 0.07 (0.12) -0.18 0.33 .53 . 
      
Depression 
Pooled Mean (95% 
CI) N studies N sample p-value I2 (%) 
HADS-D, 0–21 4.55 (3.41 to 5.69) 7 696 < .0001* 93.2 
Covariates Beta (SE) Lower CI Upper CI p-value R-squared (%) 
Age 0.07 (0.21) -0.42 0.55 .76 -67 
Percentage female gender -0.07 (0.10) -0.30 0.17 .53 -81.44 
Sample size 0.01 (0.00) 0.00 0.02 .03 100 
Disease duration -0.02 (0.04) -0.14 0.09 .59 100 
EDSS -0.53 (1.52) -5.40 4.32 .75 -112.76 
Study Quality 0.38 (0.14) 0.05 0.71 .03 100 
Publication Year -0.05 (0.15) -0.41 0.31 .75 -129.93 
      
Anxiety 
Pooled Mean (95% 
CI) N studies N sample p-value I2 (%) 
HADS-A, 0–21 6.31 (5.79 to 6.83) 7 696 < .0001* 61.2 
Covariates Beta (SE) Lower CI Upper CI p-value R-squared (%) 
Age 0.34 (0.46) -0.80 1.56 .44 -7.28 
Percentage female gender 0.11 (0.17) -0.33 0.55 .54 -11.44 
Sample size 0.04 (0.01) 0.02 0.06 .002 92.1 
Disease duration 0.04 (0.06) -0.13 0.22 .53 -21.16 
EDSS -4.27 (5.33) -27.24 18.67 .51 -11.57 
Study Quality 0.60 (0.55) -0.82 2.02 .32 3.91 
Publication Year 0.20 (0.39) -0.80 1.19 .63 -13.9 
N = number; 95% CI = 95% Confidence Interval; I2 = I-Squared Heterogeneity; * = P-value for the 
pooled mean scores of the depression or anxiety symptoms; BDI = Beck Depression Inventory;  SE = 
Standard Error; CI = Confidence Interval; EDSS = The Expanded Disability Status Scale; HADS-D = 
Hospital Anxiety & Depression Scale – Depression; HAM-D = Hamilton Depression Scale; SCL-90 = 
Symptom Checklist - 90 item; STAI = State Trait Anxiety Inventory; HADS-A = Hospital Anxiety & 
Depression Scale – Anxiety. 
All characteristics were treated as continuous variables and analysed as univariate meta-regression 
models. 
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Table 4. Methodological quality assessment of included studies on emotional outcomes in clinically isolated syndrome and early phase multiple sclerosis 
(N=51). 
Study Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9 Q10 Q11 Q12 Q13 Q14 Total Quality* 
Abdullah & Badr 2018 Yes No Other Other No No No No Yes No No No Other Yes 3/14 Poor 
Amato et al. 1995 Yes Yes Other Yes No Yes Other No Yes Yes Yes Other Other Yes 7/14 Fair 
Anhoque et al. 2011 Yes Yes Other Yes No No No Yes Yes No Yes No Other No 6/14 Fair 
Bonnett 2006 Yes Yes Yes Yes No No No Yes Yes No Yes Other Other Yes 8/14 Fair 
Brønnum-Hansen et al. 2005 Yes Yes Other Yes No Yes Yes Other Other Other Yes No Other Yes 7/14 Fair 
Calandri et al 2017 No No No Other No Other No No No No No Yes Yes No 2/14 Poor 
Cohen et al. 2017 Yes Yes Other Yes No Yes Yes No Yes Yes Yes Other No No 8/14 Fair 
de Groot et al. 2008 Yes Yes Yes Yes No Yes Yes No Yes Yes Yes Other Yes Yes 11/14 Good 
de Lima et al. 2015 Yes Yes Yes Yes No No No No Yes No Yes Other Other No 6/14 Fair 
Deloire et al. 2006 Yes Yes Yes Yes No Yes No No Yes No Yes Other Other No 7/14 Fair 
Di Legge et al. 2003 Yes No Other Other No Yes Yes No Yes Yes Yes Other Yes No 7/14 Fair 
Fazekas et al. 2013 Yes Yes Other Other No No No No Yes No Yes Other Other No 4/14 Poor 
Fredrikson et al. 2003 Yes Yes Yes Yes No Yes Yes Other Yes Other Yes No Other No 8/14 Fair 
Giordano et al. 2011 Yes Yes Yes Yes No Yes Yes Other Yes Yes Yes Other Yes Yes 11/14 Good 
Hankomaki et al. 2014 Yes Yes Other Yes No No No No No Yes Yes Other Yes No 6/14 Fair 
Heiskanen et al. 2011 Yes Yes Yes Yes No No No No Yes No Yes Other Other Yes 7/14 Fair 
Iaffaldano et al 2014 Yes Yes Other Yes No No No Yes Yes No Yes Other Other No 6/14 Fair 
Janssens et al. 2006 Yes Yes Yes No No Yes Yes No Yes Yes Yes Other Yes No 9/14 Fair 
Jonsson et al. 2006 Yes Yes Yes Yes No Yes Yes No Yes Yes Yes Other No Yes 10/14 Good 
Jun-O'Connell et al. 2017 Yes Yes Other Yes No No No No Yes Other Yes Other Other Yes 6/14 Fair 
Kern et al. 2014 Yes Yes Other Yes No No No No Yes No Yes Other Other Yes 6/14 Fair 
Kern et al. 2011 Yes Yes Other Yes No No No Other Yes Yes Yes Other Other No 6/14 Fair 
Kern et al. 2009 Yes Yes Yes Yes No No No Yes Yes No Yes Other Other No 7/14 Fair 
Kraemer et al. 2013 Yes Yes Other Yes No No No Other Yes No Yes Other Other No 5/14 Poor 
Labiano-Fontcuberta et al. 2016 Yes Yes Other Other No No No Yes Yes No Yes Other Other Yes 6/14 Fair 
Landro et al. 2004 Yes Yes Yes Yes No No No No Yes Other Yes Other Other Yes 7/14 Fair 
Langdon et al. 2013 Yes Yes Other Yes No No No No Yes No Yes Other Other No 5/14 Poor 
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Q1 = Research question clearly stated ; Q2 = Study population clearly defined; Q3 = Participation rate of eligible persons at least 50%; Q4 = Subjects selected or 
recruited from the same or similar population; Q5 = Sample size justification/statistical power of the study provided; Q6 = Exposure(s) of interest measured prior to the 
outcome(s) ; Q7 = Timeframe sufficient; Q8 = Different levels of the exposure analyzed; Q9 = Exposure measures defined in detail and reliable ; Q10 = Exposure(s) 
assessed more than once over time; Q11 = Outcome(s) measures defined in detail and reliable; Q12 = Outcome assessors blinded; Q13 = Loss to follow-up after 
baseline 20% or less; Q14 = Potential confounding variables measured and adjusted statistically; Yes = Yes (the item is fulfilled); No = No (the item is not fulfilled); 
Other = Other (cannot determine, not applicable, or not reported)
Liu et al. 2009 Yes Yes Yes Yes No No No Other Yes No Yes Other Other No 6/14 Fair 
Mattarozzi et al. 2012 Yes Yes Yes Yes No No Yes Other Yes No Yes Other Other No 7/14 Fair 
Millefiorini et al. 2002 Yes Yes Yes Yes No No No No Yes No Yes Other Other No 6/14 Fair 
Montanari et al. 2016 Yes Yes Other Yes Yes Other Yes Other Yes Other Yes Other Yes Yes 9/14 Fair 
Moreau et al. 2009 Yes Yes Yes Yes No Other Yes Yes Yes Yes Yes Other Yes No 10/14 Good 
Planche et al. 2016 Yes Yes Other No Yes Other No Other Yes No Yes Yes Other Yes 7/14 Fair 
Possa et al. 2017 Yes No No Yes No No No No No No No No Other No 2/14 Poor 
Prokopova et al. 2017 Yes Yes Other Yes No No No No Yes No Yes Other Other No 5/14 Poor 
Rojas et al. 2017 Yes Yes Other Yes No No No Other Yes No Yes Other Other Yes 6/14 Fair 
Ruet et al. 2013 Yes Yes Yes Yes No Yes Yes No Yes Yes Yes Other No Yes 10/14 Good 
Runia et al. 2015 Yes Yes Yes Yes No No Yes No Yes No Yes Other Other Yes 8/14 Fair 
Shulz et al. 2006 Yes No Other Yes No No No No Yes No Yes Other Other Yes 5/14 Poor 
Siepman et al. 2008 Yes Yes Yes Yes No No No No Yes No Yes Other Other Yes 7/14 Fair 
Simioni et al. 2008 Yes No Other Other No No No Yes Yes Yes Yes Other Other No 5/14 Poor 
Steckova et al. 2014 Yes Yes Other Yes No No No Yes Yes No Yes Other Other No 6/14 Fair 
Stenager et al. 1992 Yes Yes Yes Yes No Yes Yes No Yes Other Yes No Other Yes 9/14 Good 
Suh et al. 2010 Yes Yes Other No No No No No No No Yes No Other No 3/14 Poor 
Sullivan et al. 1997 Yes Yes Yes Yes No No No No Yes No Yes Other Other No 6/14 Fair 
Sullivan et al. 1995 Yes No Yes Yes No No No No Yes No Yes Other Other No 5/14 Poor 
Tan-Kristanto et al. 2015 Yes Yes Other No Yes No No No Yes No Yes No Other Yes 6/14 Fair 
Van der Hiele et al. 2014 Yes Yes Other Other No No No No Yes No Yes No Other Yes 5/14 Poor 
Vetrugno et al. 2007 Yes No Other No No No No No Yes Yes Yes No Other No 4/14 Poor 
Vitkova et al. 2014a Yes Yes Yes Yes No No No No Yes No Yes No Other Yes 7/14 Fair 
Vitkova et al. 2014b Yes Yes Yes Yes No No No No Yes No Yes No Other Yes 7/14 Fair 
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Figure 1. Flow chart. 
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Figure 2. Forest pot of pooled prevalence meta-analysis 
 
